# DiaMedica Therapeutics Inc. (DMAC) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $10.00, market value $539 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). DiaMedica Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1078.5×**. Each dollar of revenue is priced at 1078.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 14.1×**. The shares trade at 14.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -5.8%** (5-yr avg -16.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -58.4%**. Return on equity is negative because earnings are negative.
- **Return on assets: -9.3%**. Each dollar of assets produces -9.3% of profit.

## Growth
- **EPS growth (1 yr): -16.7%**. Earnings per share fell 16.7%.

## Financial health
- **Interest coverage: -614.6×**. Operating profit covers interest only -614.6×: fragile.
- **Current ratio: 11.81** (quick 11.81). Current assets cover the next year's liabilities 11.81 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. DiaMedica Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (4 analysts). 4 analysts cover DiaMedica Therapeutics Inc.; the consensus is strong_buy, with an average price target of $15.50 (+55% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 31.6%** (YTD 16.7%, 3-mo 42.5%). The shares are up 31.6% over twelve months including dividends.
- **From 52-week high: -4.0%** (90.7% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 63**. An RSI of 63 is neutral.
- **Beta (1 yr): 1.59** (volatility 58%). Beta of 1.59 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DMAC · Page: https://foliofundamentals.com/stocks/dmac

Not investment advice.